Israeli drugmaker BioLineRx reported data on BL-2030 at the Inflammation-Induced Cancer meeting in Jerusalem.

The data demonstrate that BL-2030, a soluble CCR2 receptor for the treatment of prostate cancer, was effective in reducing tumor growth and preventing metastasis to the lungs and bones of treated mice.

Morris Laster, BioLineRx’s CEO, said the company anticipates beginning the clinical program for the compound in 2008.

The company’s BL-1020 is in a Phase IIa study for schizophrenia, and its BL-1040 is scheduled to begin clinical studies in 2008 for the treatment of acute myocardial infarction.